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Abstract
 
Human herpesvirus 8 (HHV8, also known as Kaposi’s sarcoma [KS]-associated herpesvirus) has
been implicated as an etiologic agent for KS, an angiogenic tumor composed of endothelial, in-
flammatory, and spindle cells. Here, we report that transgenic mice expressing the HHV8-encoded
chemokine receptor (viral G protein–coupled receptor) within hematopoietic cells develop an-
gioproliferative lesions in multiple organs that morphologically resemble KS lesions. These le-
sions are characterized by a spectrum of changes ranging from erythematous maculae to vascu-
lar tumors, by the presence of spindle and inflammatory cells, and by expression of vGPCR,
CD34, and vascular endothelial growth factor. We conclude that vGPCR contributes to the
development of the angioproliferative lesions observed in these mice and suggest that this
chemokine receptor may play a role in the pathogenesis of KS in humans.
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Introduction
 
Kaposi’s sarcoma (KS),
 
1
 
 which was first described by Moriz
Kaposi in 1872, may be clinically divided into four distinct
forms: rare classical KS, more common posttransplant and
AIDS-associated KS, and endemic KS, which is common
in equatorial Africa (1). Histopathologically, this multifocal
tumor is characterized by an angiogenic proliferation of mes-
enchymal cells with the formation of slit-like vascular spaces
surrounded by spindle cells and infiltrating inflammatory
cells. An infectious etiology for KS was first proposed in
1994, when Chang et al. (2) discovered a novel human her-
 
pesvirus (human herpesvirus 8 [HHV8], or KS-associated
herpesvirus [KSHV]) during systematic DNA screening of
KS lesions. In recent years, epidemiological and experimen-
tal studies have strengthened the link between this lympho-
tropic herpesvirus and KS by showing that HHV8 infection
precedes development of tumors, tracks tightly with KS
risk, and targets spindle cells (3–5). Furthermore, HHV8
encodes several genes with angiogenic and transforming
properties that may be important for the development of
KS (6). One such gene (ORF74) encodes a constitutively
active viral G protein–coupled receptor (vGPCR) that binds
several host CC and CXC chemokines (7, 8). Transient
transfection of this receptor into fibroblasts causes intracellu-
lar accumulation of inositol phosphate (7), increased cellular
proliferation, and expression of vascular endothelial growth
factor (VEGF; reference 9), a potent angiogenic factor.
Taken together, these results strongly suggest a link be-
tween HHV8 and KS in vivo, but they do not prove that
HHV8 is sufficient for KS development nor define which
HHV8 genes are relevant for pathogenesis. To start ad-
dressing the biological function of HHV8-encoded genes
in vivo, we generated transgenic mice expressing vGPCR
under the control of the human CD2 promoter (10).
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Materials and Methods
 
Generation of Transgenic Mice.
 
The coding sequence for vGPCR
was amplified from the genomic DNA of BC-1 cells (American
Type Culture Collection) with primers TY42 (5
 
9
 
-GGAATTC-
ACCACCATGGCGGCCGAGGATTTCC-3
 
9
 
) and TY10 (5
 
9
 
-
ATCCTGCAGGGGCTACGTGGTGGCGCCGGACAT-3
 
9
 
).
Sequencing of the amplified fragment showed it to be identical to
the gene described by Cesarman et al. (3). The 1.0-kb vGPCR
fragment was cloned into EcoRI–SmaI sites of a plasmid contain-
ing the human CD2 enhancer/promoter and locus control region
(10). Generation and genotypic analyses of the animals were done
as previously described (11). The resulting transgenic animals
were kept under pathogen-free conditions.
 
RNA Analysis.
 
RNA was extracted from tissues or sorted
cells using Ultraspec RNA, following specifications from the
manufacturer (Biotecx). Total RNA (20 
 
m
 
g) was denatured and
blotted onto GeneScreen membrane (New England Nuclear). A
1.0-kb fragment of the vGPCR DNA was radiolabeled and was
used as a probe in these experiments. For reverse transcriptase
(RT)-PCR, cDNA was synthesized from 2 
 
m
 
g of total RNA
primed with oligo-(dT)12-18 using the Superscript II Preamplifi-
cation System (GIBCO BRL). 2–5 
 
m
 
l of cDNA was amplified in
a 50-
 
m
 
l reaction volume under the following conditions: 94
 
8
 
C
for 1 min and 35 cycles of 94
 
8
 
C for 1 min, 60
 
8
 
C for 1 min, 72
 
8
 
C
for 2 min and then incubated in a GeneAmp
 
®
 
 PCR System (Per-
kin-Elmer Cetus). The oligonucleotide primers corresponding
to the sense and antisense strands, respectively, were as follows:
vGPCR, 5
 
9
 
-ATGGCGGCCGAGGATTTCCTAACC-3
 
9
 
 and
5
 
9
 
-AGGTACCTCACTAGACTGACGCAC-3
 
9
 
; and G3PDH,
5
 
9
 
-TGAAGGTCGGTGTGAACGGATTTGGC-3
 
9
 
 and 5
 
9
 
-CAT-
GTAAGGCCATGAGGTCCACCAC-3
 
9
 
. The final PCR prod-
ucts were analyzed on a 2% agarose gel containing ethidium
bromide.
 
Human IFN-
 
g
 
–inducible Protein 10 Binding Assay.
 
Thymocytes
(10
 
6 
 
cells per point) were resuspended in binding buffer (50 mM
Hepes, 1 mM CaCl
 
2
 
, 5 mM MgCl
 
2
 
, 0.5% BSA) and incubated
with 0.1 nM of radiolabeled human IFN-
 
g
 
–inducible protein
(hIP-10; NEN Life Science Products) in the absence or presence
of 100 nM of unlabeled human IP-10 in 96-well plates. After 2 h
at room temperature, plates were spun down, and cell pellets were
resuspended in binding buffer supplemented with 0.5 M NaCl.
Cells were spun through 10% glycerol in binding buffer with 0.5 M
NaCl. Cell pellets were frozen in liquid nitrogen, clipped, and
counted. All experiments were performed in triplicate.
 
Histochemistry, Immunohistochemistry, Electron Microscopy, and In
Situ Hybridization.
 
Tissues were either fresh-frozen for cryosec-
tion or were fixed, processed, and stained with hematoxylin and
eosin. For immunostaining, fresh-frozen sections were fixed with
acetone, and rehydrated paraffin sections were subjected to anti-
gen retrieval first. For transmission electron microscopy, tissues
were collected in 2.5% glutaraldehyde and then submitted for
standard osmium fixation and plastic embedding. Thin sections
were placed on grids and examined using an LEO electron mi-
croscope (Zeiss Instruments). For immunohistochemical staining,
anti-CD34 antibody was provided by Dr. A. Mantovani (Insti-
tuto di Ricerche Farmacologiche Mario Negri, Milan, Italy).
Anti-CD3, anti-F4/80 (Serotec Ltd.), anti-B220, and anti-
CD11b/Mac-1 (PharMingen) were also used in the experiments.
Binding of the antibody was detected with a Vectastain Elite
ABC kit (Vector Labs., Inc.). DAB and AEC kits from Vector
were used as substrates for peroxidase. Hematoxylin was used for
counterstaining.
 
 
 
In situ hybridization was carried out as described
(12). Sense and antisense 
 
33
 
P-labeled riboprobes were transcribed
 
from cDNA templates of vGPCR (from nucleotides 473–1,075)
or VEGF (from nucleotides 91–429) with either T7 or T3 poly-
merase (Boehringer Mannheim).
 
Bone Marrow Transplantation.
 
Sterile bone marrow cells were
flushed out from femurs of CDVG (CD2 promoter–vGPCR)
and control mice. Single-cell suspensions (10
 
7
 
 cells) were injected
into the tail veins of lethally irradiated (1,100 rads for 5 min)
B6D2 F1 mice (6–8 wk old).
 
Cell Sorting.
 
Single-cell suspensions were prepared from
CDVG spleens by passage through a 100-
 
m
 
M nylon cell strainer
(Falcon-Becton Dickinson) in RPMI medium containing 5%
FCS. RBCs were lysed, and the remaining cells were washed and
resuspended in 1
 
3
 
 PBS containing 0.5% BSA and 2 mM EDTA
(buffer A). To prevent nonspecific binding of the antibodies, Fc
(CD16/CD32) receptors were blocked by incubating in buffer A
containing 5 
 
m
 
l of Fc Block (PharMingen) and 300 
 
m
 
g/ml of
whole mouse IgG per 10
 
6
 
 cells for 10 min at room temperature.
Dead and apoptotic cells were removed using the Dead Cell Re-
moval kit from Miltenyi Biotec as per the manufacturer’s recom-
mendations. Directly conjugated microbeads (Miltenyi Corp.)
were used to isolate cell populations expressing Mac-1 (CD11b),
B220, and Thy1.2. To isolate NK cells, we used DX5 antibodies
conjugated with biotin and subsequently used streptavidin micro-
beads as per the manufacturer’s recommendations. Flow cyto-
metric analysis of these sorted cells showed that they were 83–
92% pure. 10
 
7
 
 cells in each case were used for RNA isolation.
CD2
 
1
 
 cells from tumors were isolated as follows: Solid tumors
were excised from CDVG mice, minced, and incubated for 20
min at 37
 
8
 
C in RPMI containing 5% FCS, 10 mM Hepes/5%
FBS, 1 mM MgCl
 
2
 
, 1.8 mM CaCl
 
2
 
, 0.5 mg/ml collagenase D
(Boehringer Mannheim), and 35 U/ml DNAse I (Sigma Chemi-
cal Co.). This suspension was passed through a wire mesh to
eliminate debris, and the incubation was continued for an addi-
tional 20 min at 37
 
8
 
C. At the end of the incubation, cells were
passed through a 100-
 
m
 
m mesh and pelleted at 1,000 rpm for 10
min at 4
 
8
 
C. The RBCs were lysed, the Fc receptors were
blocked, and the dead cells were removed as described above. The
cells were pelleted and resuspended in buffer A containing bi-
otin-conjugated anti-CD2 at a predetermined concentration, and
the suspension was incubated for 15 min at 4
 
8
 
C on a rotator. The
cells were washed in buffer A, and the CD2
 
1
 
 cells were isolated
using Strep microbeads (Miltenyi Corp.) as per the manufac-
turer’s recommendations. Sorted cells were 85–90% pure.
 
Results
 
Expression of vGPCR within Hematopoietic Cells of
Transgenic Mice.
 
Because HHV8 is a member of the lym-
photropic subgroup of herpesviruses (6) and its presence
has been detected in blood mononuclear cells (13), we rea-
soned that cells of hematopoietic origin may represent a
good experimental system to study vGPCR effects in vivo.
To this end, we used an expression vector containing the
human CD2 promoter, which primarily targets gene ex-
pression to hematopoietic cells (Fig. 1 A).
 
 
 
We obtained
seven transgenic founders, from which five transgenic lines
were derived. We refer to these transgenic mice as CDVG
(CD2 promoter–vGPCR) mice. Transgene expression was
initially evaluated by Northern blot analysis. The vGPCR
transcripts were detected in thymi and bone marrow of 
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transgenic but not of control mice, consistent with the well
documented pattern of transgene expression driven by the
CD2 promoter (reference 14; Fig. 1 B). To investigate the
transgene expression in different hematopoietic cells, we
isolated leukocyte subsets by magnetic sorting, extracted
RNA, and performed RT-PCR. As shown in Fig. 1 C,
vGPCR transcripts could be amplified from NK and T
cell–enriched populations but not from B cells or Mac-1
 
1
 
cells. These results point to a predominant expression of
the transgene in T and NK cells. Next, we examined the
expression of vGPCR at the cell surfaces of transgenic thy-
mocytes by measuring binding of radiolabeled human
(h)IP-10, a chemokine known to inhibit constitutive vG-
PCR signaling (15). Thymocytes from vGPCR-transgenic
mice showed more than a fivefold increase of radiolabeled
hIP-10 binding compared with control thymocytes (Fig.
1 C). Binding of hIP-10 to transgenic thymocytes could be
reduced by competition with unlabeled hIP-10. Increased
binding of hIP-10 to transgenic thymocytes was not related
to binding to its murine homologue receptor, CXCR3,
because mCXCR3 expression was not detected in trans-
genic thymi by Northern blot analysis (data not shown).
These results confirmed the expression of vGPCR within
hematopoietic cells of transgenic mice.
 
CDVG Mice Develop Angioproliferative Disease within Mul-
tiple Organs.
 
Mice expressing vGPCR were normal at birth.
However, within the first 30–90 d of life, all transgenic
mice from three independent lines (9, 19, and 122) devel-
oped lesions that initially consisted of erythematous to pur-
plish
 
 
 
maculae and plaques that subsequently progressed to
purple nodules and eventually to overt tumors on the ears,
tail, nose, and paws (Fig. 2, A–E). Erythematous nodules
were also seen in skeletal muscle and in the walls of the
small and large intestine (Fig. 2 F). Microscopically, the
CDVG tumors were multicentric angioproliferative lesions
that were nodular and grew between or invested normal
structures of skin (Fig. 3 A). Similar lesions were detected
occasionally in heart, skeletal muscle, and the submucosa
and muscularis propria of the small and large intestine.
They were characterized by sarcomatoid appearing sheets
and fascicles of spindled cells forming slit-like and round
vascular spaces that contained erythrocytes (Fig. 3, B and
C). Mitotic figures were uncommon, and necrotic cells were
rare. In addition, the CDVG lesions showed strong expres-
sion of CD34, an endothelial cell marker present in angio-
genic tumors, including KS tumors (Fig. 3 D; reference 16).
To confirm the light microscopic impression and to ex-
clude the possibility of other vascular-rich neoplasms, le-
sions from multiple sites were examined by transmission
electron microscopy. At the ultrastructural level, the lesions
from different sites were similar and composed of endothe-
lial cells forming vascular spaces within a loose collagen
matrix. Erythrocytes were often present within vascular lu-
mina (Fig. 4, top panels). The endothelial cells lining vas-
cular spaces showed typical features of tight junctions and
micropinocytotic vesicles. Pericytes were present in vari-
able numbers. As described for human KS, Weibel-Palade
bodies were absent (17). More primitive spindled cells were
identified in the interstitial spaces. These less differentiated
cells had a cytoplasm with prominent rough endoplasmic
reticulum with scattered mitochondria and lysosomes.
These were observed in various stages of lumen formation
and thus appeared to be endothelial cell precursors. There
was no evidence of epithelial, mesothelial, fibrohistiocytic,
rhabdoid, or neuroid differentiation.
Scattered throughout the vascular lesions were hemosid-
erin deposits and variable numbers of mixed inflammatory
cells, including macrophages, eosinophils, mast cells, neutro-
phils, and lymphocytes. Occasional extravasated erythrocytes
and inflammatory cells were also present in the interstitium
(Fig. 4, top panels). To further phenotype the leukocytes
present within the lesions, we performed immunohisto-
chemistry (Fig. 4, bottom panels). The lymphocytes de-
tected by light and electron microscopy were mostly T
cells. Other lymphocytes, such as B cells, were also found,
but at lower frequency. Macrophages, visualized by F4/80
Figure 1. Generation and expression analysis of CDVG-transgenic mice. (A) Structure of the CDVG transgene. (B) Northern blot analysis of bone
marrow (BM) and thymus RNA from control and CDVG-transgenic mice (transgenic lines 7, 19, and 122). The BM blot was exposed three times
longer than the thymus blot. Bottom panel shows the ethidium bromide–stained RNA gels. (C) RT-PCR analysis of transgene expression in subsets of
cells isolated from the spleens of transgenic mice. Expression of the transgene was detected in NK (NK1) and T (Thy1.21) but not in B (B2201) and
myeloid (Mac-11) cell–enriched populations. (D) Radiolabeled hIP-10 binding to the transgenic and control thymocytes. Binding of radiolabeled hIP-
10 to transgenic thymocytes can be displaced by cold hIP-10 (CDVG1hIP-10). 
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immunostaining, could also be found within the lesions.
These results confirm the presence of several types of in-
flammatory cells within the lesions. Taken together, the
histologic and ultrastructural features described above sug-
gested a Kaposi-like angioproliferative neoplasm with infil-
tration of inflammatory cells.
 
vGPCR and VEGF Are Expressed within Angioproliferative
Lesions.
 
To investigate whether the vascular changes ob-
served in the CDVG mice were associated with the expres-
sion of vGPCR, we performed RT-PCR and in situ hy-
bridization studies. Transgene transcripts were detected in
samples with macroscopic lesions (ear, muscle) but were not
found in transgenic tissue samples that lacked lesions (Fig.
5 A and Fig. 5 C, left panel). As the transgene expression
was directed by CD2 regulatory elements, we investigated
whether CD2
 
1
 
 cells could be found within the lesions. To
this end, we isolated CD2
 
1
 
 cells from the tumors using
magnetic sorting. Next, we investigated if these CD2
 
1
 
 cells
expressed the transgene by RT-PCR analysis. As shown in
Fig. 5 B, transgene expression could be detected by RT-PCR
in these CD2
 
1
 
 cells. To investigate the distribution of the
vGPCR-expressing cells, we performed in situ hybridiza-
tion. Interestingly, similar to human KS (18), vGPCR ex-
pression can be detected in a subset of cells within the le-
sion (Fig. 5 C, left panel). Morphologically, most of these
cells were either round or oval- shaped; we only rarely de-
tected expression in spindle-shaped cells.
The fact that vGPCR expression took place in some but
not all cells within the tumor could suggest that vGPCR ex-
pression may influence tumor growth by an indirect mecha-
nism. In vitro, vGPCR induces the expression of VEGF (9),
a potent angiogenic factor. Expression of VEGF by a small
number of cells could conceivably result in significant vascu-
lar proliferation. To determine whether VEGF was expressed
within the transgenic lesions, we performed in situ hybridiza-
tion. We found that, within the same lesion, VEGF was ex-
pressed by a few scattered cells, in a pattern of expression that
closely resembled that of the transgene (Fig. 5 C, right panel).
These results suggest that cells expressing vGPCR may also
express VEGF and that VEGF may be involved in the devel-
opment of the vascular lesions. It is unlikely, however, that
VEGF alone accounts for all of the phenotypes observed in
CDVG
 
 
 
mice, because transgenic animals expressing VEGF
develop milder angiogenic changes (19, 20) and, more im-
Figure 2. KS-like lesions in CDVG-trans-
genic mice. Shown are (A) an erythematous,
sharply-bordered plaque on the ear; (B) later
lesions showing raised purplish or erythema-
tous nodules and tumors on the ear, (C) tail,
(D) nose, and (E) paw; and (F) erythematous
nodules in wall of the small intestine (one is in-
dicated by the white arrowhead). 
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portantly, the lesions described in VEGF-transgenic mice did
not evolve into the sarcoma-like lesions observed here. Addi-
tional factors may thus be involved in the generation of the
lesions observed in CDVG mice.
 
Animals Transplanted with Bone Marrow from CDVG Mice
Develop Angioproliferative Disease.
 
In a separate set of ex-
periments, we were able to observe KS-like disease in an-
imals in which vGPCR expression was driven by a CMV
enhancer–
 
b
 
-actin promoter element (our unpublished ob-
servations). Three founders expressing vGPCR developed
a disease that was clinically and histologically indistin-
guishable from the one described above. However, we
were unable to propagate lines from these founders, due
to either extreme mosaicism or early lethality of the posi-
tive offspring. The occurrence of disease in these animals
could be due to expression of vGPCR in multiple tissues,
raising the possibility that the disease observed in the
CDVG mice could be due to ectopic expression of the
transgene. To further demonstrate that the disease-caus-
ing cells in the CDVG mice had a hematopoietic origin
and to rule out the possibility that the phenotype ob-
served in the CDVG mice was due to ectopic expression
of the transgene, we transplanted bone marrow from
CDVG or control mice into lethally irradiated wild-type
 
animals. In contrast to mice receiving control bone mar-
row, CDVG bone marrow–transplanted mice clearly
showed the presence of the transgene in bone marrow
cells (Fig. 6 A). 7 mo after transplantation, the recipients
of control bone marrow (
 
n
 
 5 
 
3) were disease free, but
two out of three of the animals transplanted with CDVG
bone marrow developed small purplish nodules at the
bases of their tails (Fig. 6 B). Clinically and histopatholog-
ically, these lesions shared all of the characteristics of
tumors seen in CDVG mice. Angioproliferative lesions
were nodular and grew below a normal epidermis within
the dermal compartment of the skin (Fig. 6 C). As in the
donor strain, the tumors showed spindle-shaped cells
forming slit-like vascular spaces that contained erythro-
cytes and variable numbers of mixed inflammatory cells
(Fig. 6 D). These results, therefore, demonstrate that this
angioproliferative disease can be transferred by bone mar-
row transplantation, suggesting that cells of hematopoietic
origin play a crucial role in its pathogenesis.
 
Discussion
 
Although epidemiological evidence suggests an infectious
etiology for KS and clearly links this multicentric angiopro-
Figure 3. Microscopic changes in CDVG mice. (A) Tail. Multiple nodular angioproliferative tumors located in the dermal compartment of the skin.
(B) Tail. Large numbers of spindle-shaped cells arranged in interlacing fascicles. Blood vessels are lined by plump endothelial cells and surrounded by oval
to spindle-shaped cells. (C) Ear. Border between interlacing fascicles of spindle-shaped cells. There are irregular vascular clefts between cells that contain
erythrocytes. (D) Immunohistochemical staining of a typical angioproliferative lesion with anti-CD34. Numerous positively stained cells are present. 
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Figure 4. Analysis of angio-
proliferative lesions. Top panels:
ultrastructural analysis of angio-
proliferative tumors. Panels de-
pict representative areas taken
from skin and pericardial tumors.
Note numerous vascular spaces
(V) lined by endothelial cells (E)
and containing erythrocytes (*)
and occasional lymphocytes (L).
Extravasated erythrocytes are
also present in interstitium with
nearby macrophages (M), top left
panel. Spindled endothelial cell
precursors (Ep) are among vessels
with occasional inflammatory
neutrophils (N), top right panel.
Bottom panels: immunohis-
tochemical staining of angiopro-
liferative lesions. Positive cells
are stained red. Notice the pres-
ence of cells staining for CD3,
F4/80, and B220 (arrowheads).
Figure 5. Detection of the ex-
pression of vGPCR and VEGF
within angioproliferative lesions
of CDVG mice. (A) RT-PCR
analysis of vGPCR expression
within ears and muscle from ani-
mals in two separate transgenic
lines of CDVG mice, 19 and
122. Samples obtained from tis-
sues with gross lesions (1) and
without lesions (2) were used.
Amplification of a segment of
G3PDH was used as an internal
control for the reactions. (B)
Magnetically sorted CD21 cells
found within tumors express
vGPCR. Positive (1) and neg–
ative (2) controls for this reac-
tion were thymi from transgenic
and control mice, respectively.
No signal was observed in CD2
samples not reverse transcribed,
indicating that the signal was de-
rived from transgenic transcripts
rather than genomic DNA. (C)
In situ hybridization analysis of
the expression of vGPCR and
VEGF within the muscle of
CDVG mice, dark field. The sil-
ver grains are only associated
with infiltrating cells in the le-
sion. No signals found in the mus-
cle cells (indicated by white *).
Inset, higher magnification of the
boxed area, bright field. 
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liferative disease with HHV8 infection, the functional role
of this lymphotropic herpesvirus in the pathogenesis of KS
has remained unclear (6, 21, 22). A major limitation in ad-
dressing this critical question has been the lack of an exper-
imental animal model. To circumvent this limitation, we
began a systematic analysis of the biological properties of
HHV8-encoded genes using transgenesis. Here, we report
that a single gene of HHV8 is sufficient to induce in mice
an angioproliferative disease that bears striking similarity to
human KS. Clinically, the lesions start as erythematous
maculae or plaques and progress to violaceous, purplish
nodules and tumors that develop predominantly in the skin
and to a lesser extent in intestine, heart, and skeletal mus-
cle. Histologically and ultrastructurally, these lesions show
characteristics similar to those of human KS and Kaposi-
form hemangioendotheliomas. Lesions within the skin de-
veloped and spread within the dermis while sparing the
overlying epidermis. Like KS, the nodular angioprolifera-
tive tumors formed slit-like vascular spaces containing
erythrocytes and were surrounded by spindle cells and infil-
trating inflammatory cells (16, 21, 23, 24). Finally, vG-
PCR, VEGF, and CD34, markers that have been detected
in KS, are also detected within these lesions (18, 25–27).
The angioproliferative disease observed in the CDVG
animals is most likely caused by cells of hematopoietic ori-
gin, because control mice transplanted with CDVG bone
marrow cells develop disease. It is unclear at this point,
however, whether the cell responsible for disease develop-
ment is a common hematopoietic cell or a rare, immature
cell, such as an endothelial cell precursor (28, 29). Indepen-
dent of the precise nature of this cell, it is likely that it ex-
presses CD2, as CD2 regulatory elements were used to tar-
get expression of the transgene. In mice, CD2 is expressed
in thymocytes, T cells, NK cells, and B cells. The CD2
promoter used in our experiment, however, primarily tar-
gets a subset of these cells, more specifically T lymphocytes
(10) and NK cells. Thus, if the disease is caused by a com-
mon hematopoietic cell, the most likely candidates for in-
ducing it would be T lymphocytes (mature or immature)
and NK cells. A number of other hematopoietically de-
rived cells are also present in the lesions, including B cells
and macrophages. However, Northern blot analysis of B cell–
rich tissues such as Payer’s patches (data not shown) and
RT-PCR analysis of B cells extracted from the spleen
failed to show transgene expression, indicating that these
cells do not express the transgene at appreciable levels.
Other cells found in the lesions include macrophages, but
preparations of peritoneal macrophages (not shown) and
Mac-1
 
1
 
 cells from spleens were negative for transgene ex-
pression. We cannot exclude, however, that low level ex-
pression of vGPCR by these or other cell populations
could be important for the pathogenesis of the KS-like dis-
ease observed here. The resolution of this matter will
clearly require the development of specific reagents to im-
munophenotype the cell expressing the transgene within
the lesion and the demonstration through genetic and adop-
tive transfer experiments that expression of vGPCR by this
cell can lead to development of disease.
Based on the results obtained with the bone marrow
transplants, we propose that disease development involves
homing of circulating vGPCR-expressing cells to different
tissues. These cells may have physiologically homed to
these tissues or may have abnormally migrated due to the
constitutive expression of this viral chemokine receptor on
their surfaces. Once these vGPCR-expressing cells homed
to their appropriate environment, they may have contrib-
uted to the intense vascular proliferation and inflammatory
cell recruitment that we observed. Although we cannot
Figure 6. Transplantation of bone marrow
cells from CDVG mice induces angioprolifera-
tive tumors in recipient mice. (A) PCR analysis
of the vGPCR gene in genomic DNA of bone
marrow of wild-type (lane 1) and CDVG bone
marrow–transplanted mice (lane 2). Lane 3 rep-
resents the vGPCR control plasmid (250 bp,
lower band). The upper band is the 383-bp in-
ternal control band from the LDL gene. (B)
Tail. Purplish nodular tumor developed 7 mo
after bone marrow transplantation. (C) Tail.
Nodular angioproliferative tumor within the
dermis. (D) Tail. Formation of vascular clefts
containing erythrocytes surrounded by spindle
and inflammatory cells. 
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rule out that the incoming cell may proliferate as function
of vGPCR expression, we favor an indirect, paracrine
mechanism for the vascular proliferation, because few of
the cells within the lesion are expressing vGPCR. One of
these paracrine factors is VEGF, which has been shown to
be an important requirement for the growth of cells la-
tently infected with HHV8 and development of KS in hu-
mans (9, 27, 30).
It has been proposed that in KS (contrary to other mod-
els of virus-induced tumorigenesis), the growth of latently
infected cells may be critically dependent on paracrine fac-
tors produced by neighboring cells undergoing a switch
from latency to the lytic cycle (18, 31). Studies done in cell
culture and in KS tumors have shown that vGPCR, vIL-6,
viral macrophage inflammatory protein I, and vBcl2 are ex-
pressed by few infected cells in the early lytic phase of the
life cycle of HHV8 (18, 31), but it has been unclear
whether these lytic cycle products could account for any of
the pathogenesis of KS. Results reported here show that
vGPCR is sufficient to induce in mice an angioprolifera-
tive disease that has remarkable similarities to KS, adding
additional support to the notion that HHV8 is an etiologic
agent of this disease. Furthermore, they suggest that para-
crine mechanisms triggered by the expression of this
chemokine receptor play an important role in the develop-
ment of angioproliferative diseases such as KS. Taken to-
gether, these observations implicate vGPCR expression
during the lytic phase of HHV8 infection as an important
factor in the pathogenesis of KS and suggest that vGPCR
may represent a novel target for therapeutic intervention.
Further studies in these directions should be facilitated by the
development of the animal model described in this report.
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